StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHXFree Report) in a report issued on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The stock has a market capitalization of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a one year low of $0.01 and a one year high of $1.99.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.